DelveInsight’s “Persistent Epithelial Defect Pipeline Insights 2026” report provides comprehensive insights about 5+ Persistent Epithelial Defect Companies and 5+ pipeline drugs in the Persistent Epithelial Defect pipeline landscape. It covers the Persistent Epithelial Defect pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Persistent Epithelial Defect therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead in understanding the Persistent Epithelial Defect Treatment Landscape @ Persistent Epithelial Defect Pipeline Outlook

Key Takeaways from the Persistent Epithelial Defect Pipeline Report

• In February 2026, Krystal Biotech Inc. initiated a phase 1/2 study eye daily for 8 weeks. Subjects will return for a follow-up visit 2 weeks after finishing treatment to monitor for safety and durability of corneal healing. Safety follow-up visits will then occur every 3 months through approximately 1 year on study.
• DelveInsight’s Persistent Epithelial Defect Pipeline report depicts a robust space with 5+ Persistent Epithelial Defect companies working to develop 5+ pipeline therapies for Persistent Epithelial Defect treatment.
• The leading Persistent Epithelial Defect Companies such as Eyevance/Amber Ophthalmics, Kala Pharmaceuticals, Noveome Biotherapeutics, Oyster Point Pharma and others.
• Promising Persistent Epithelial Defect Pipeline Therapies such as KIO-201, DE-105 ophthalmic solution, ST266, Lufepirsen High Dose, KB801, and others.

Gain in-depth knowledge of key Persistent Epithelial Defect clinical trials, emerging drugs, and market opportunities @ Persistent Epithelial Defect Clinical Trials Assessment

Persistent Epithelial Defect Overview

The cornea is the transparent, outermost layer of the eye that uniformly refracts the majority of light that enters the eye onto the lens and is essential for ideal vision. The multi-layered corneal epithelium acts as a protective barrier to infectious agents via tight junctions between neighboring cells, and it maintains its smooth optical surface by constantly regenerating cells in the basal cell layer. Persistent Corneal Epithelial Defects (PCEDs) (PEDs or PCEDs) result from the failure of rapid re-epithelialization and closure within 10-14 days after a corneal injury, even with standard supportive treatment. Disruptions in the protective epithelial and stromal layers of the cornea can render the eye susceptible to infection, stromal ulceration, perforation, scarring, and significant vision loss.

Persistent Epithelial Defect Emerging Drugs Profile

• KPI-012: Kala Pharmaceuticals

Kala’s development pipeline includes KPI-012, in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. Kala is also evaluating KPI-012 for potential expansion to additional indications for rare front of the eye diseases, such as partial limbal stem cell deficiency and moderate-to-severe Sjögren’s. KPI-012 is currently under investigation for PCED in Phase II trial which is expected to be completed in February 2024.

• Nexagon: Eyevance/Amber Ophthalmics

NEXAGON, is a first in class unmodified antisense oligodeoxynucleotide that inhibits a cell membrane hemichannel forming protein, connexin43 (Cx43). Cx43 is overexpressed after acute injury or in chronic disease states leading to pathological prematurely open hemichannels, allowing ATP to enter the extracellular space. Extracellular ATP triggers and perpetuates the immune system’s inflammasome pathway releasing multiple proinflammatory cytokines resulting in microvascular breakdown, vessel leak and limbal tissue ischemia.

The Persistent Epithelial Defect Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Persistent Epithelial Defect with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Persistent Epithelial Defect Treatment.
• Persistent Epithelial Defect Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Persistent Epithelial Defect Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Persistent Epithelial Defect market

Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Persistent Epithelial Defect Unmet Needs

Persistent Epithelial Defect Companies

Eyevance/Amber Ophthalmics, Kala Pharmaceuticals, Noveome Biotherapeutics, Oyster Point Pharma and others.

Persistent Epithelial Defect pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Persistent Epithelial Defect Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

See the latest progress in drug development and clinical research @ Persistent Epithelial Defect Market Drivers and Barriers, and Future Perspectives

Scope of the Persistent Epithelial Defect Pipeline Report

• Coverage- Global
• Persistent Epithelial Defect Companies- Eyevance/Amber Ophthalmics, Kala Pharmaceuticals, Noveome Biotherapeutics, Oyster Point Pharma and others.
• Persistent Epithelial Defect Pipeline Therapies- KIO-201, DE-105 ophthalmic solution, ST266, Lufepirsen High Dose, KB801, and others.
• Persistent Epithelial Defect Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Persistent Epithelial Defect Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Access the Full Persistent Epithelial Defect Pipeline Analysis Today! @ Persistent Epithelial Defect Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. Persistent Epithelial Defect: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Persistent Epithelial Defect– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. KPI-012: Kala Pharmaceuticals
11. Drug profiles in the detailed report…..
12. Early Stage Products (Phase I/II)
13. OC-01: Oyster Point Pharma
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. Drug profiles in the detailed report…..
17. Inactive Products
18. Persistent Epithelial Defect Key Companies
19. Persistent Epithelial Defect Key Products
20. Persistent Epithelial Defect- Unmet Needs
21. Persistent Epithelial Defect- Market Drivers and Barriers
22. Persistent Epithelial Defect- Future Perspectives and Conclusion
23. Persistent Epithelial Defect Analyst Views
24. Persistent Epithelial Defect Key Companies
25. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/persistent-corneal-epithelial-defects-pceds-pipeline-insight